Prof. Dr. Hulya Ayar Kayali is an esteemed professor at Dokuz Eylül University, where she specializes in biochemistry and biotechnology, with a particular focus on cancer biology and cell development. Since completing her graduate education at DEU's Institute of Science and Technology, she has contributed significantly to both academia and industry. Prof. Kayali's research encompasses a wide range of topics including the characterization of enzymes and antibiotics in bacterial models, the investigation of cancer signaling pathways, and the development of diagnostic and therapeutic tools for ovarian and colon cancer.

Her postdoctoral work continued with extensive research into bacterial and mammalian cell cultures, training numerous graduate students and professionals. As a leader in her field, she has directed significant projects with multiple national and international partners through Tübitak, Tüseb, and others. In 2018, she also founded ID Biofarma Biotechnology Company within DEU DEPARK, leading innovative projects in drug development such as the production of biosimilar monoclonal antibodies and the synthesis of antibody-drug conjugates.

Her work with biosimilars includes the development of a monoclonal antibody from initial design to large-scale production and characterization in line with EMA standards, and her research uses advanced techniques like HPLC, Capillary Electrophoresis, and Surface Plasmon Resonance. Prof. Kayali's expertise extends to creating next-generation drugs using cutting-edge technologies such as nanoparticles and exosomes. Recognized for her competence in high-tech, high-budget projects, she is adept in meeting regulatory standards set by entities like the FDA and EMA.